aromasil has been researched along with Obesity in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ | 1 |
| Akıncı, MB; Aksoy, S; Altundag, K; Dede, DŞ; Ozdemir, N; Şendur, MA; Yalçın, B; Zengin, N | 1 |
| Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC | 1 |
| Cadirni, A; Campagna, S; Francini, E; Francini, G; Gonnelli, S; Montagnani, A; Petrioli, R | 1 |
3 trial(s) available for aromasil and Obesity
| Article | Year |
|---|---|
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors | 2013 |
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Disease-Free Survival; Female; Humans; Lipid Metabolism; Middle Aged; Obesity; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triglycerides | 2006 |
1 other study(ies) available for aromasil and Obesity
| Article | Year |
|---|---|
Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Obesity; Ovary; Receptors, Estrogen; Treatment Outcome | 2015 |